Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
SAB Biotherapeutics Inc banner
S

SAB Biotherapeutics Inc
NASDAQ:SABS

Watchlist Manager
SAB Biotherapeutics Inc
NASDAQ:SABS
Watchlist
Price: 3.98 USD -5.91%
Market Cap: $189.5m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SABS Price Targets Summary
SAB Biotherapeutics Inc

Wall Street analysts forecast SABS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SABS is 9.56 USD with a low forecast of 5.05 USD and a high forecast of 15.75 USD.

SABS Lowest Forecast
Wall Street Target
5.05 USD
27% Upside
SABS Average Forecast
Wall Street Target
9.56 USD
140% Upside
SABS Highest Forecast
Wall Street Target
15.75 USD
296% Upside
Lowest
Price Target
5.05 USD
27% Upside
Average
Price Target
9.56 USD
140% Upside
Highest
Price Target
15.75 USD
296% Upside
SAB Biotherapeutics Inc Competitors:
Price Targets
MASI
Masimo Corp
38% Upside
F
FLB
Fluidigm Corp
23% Upside
LAND
Gladstone Land Corp
0% Downside
MASI
Masimo Corp
38% Upside
F
FLB
Fluidigm Corp
23% Upside
LAND
Gladstone Land Corp
0% Downside

Revenue
Forecast

-72% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
-72% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

For the last 3 years the compound annual growth rate for SAB Biotherapeutics Inc's revenue is -72%. The projected CAGR for the next 4 years is 53%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
11%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
11%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-81%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-81%
Average Miss

What are analyst estimates?

See Also

Summary
SABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
SABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SABS stock valuation using valuation multiples.
Wall Street Estimates
SABS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SABS's stock price target?
Price Target
9.56 USD

According to Wall Street analysts, the average 1-year price target for SABS is 9.56 USD with a low forecast of 5.05 USD and a high forecast of 15.75 USD.

What is SAB Biotherapeutics Inc's Revenue forecast?
Projected CAGR
53%

For the last 3 years the compound annual growth rate for SAB Biotherapeutics Inc's revenue is -72%. The projected CAGR for the next 4 years is 53%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 315,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.